NICE Rejects Donanemab: Treatment Cost-Effectiv...

By HEOR Staff Writer

June 19, 2025

How cost-effective is donanemab as an Alzheimer’s treatment, and why did NICE reject its routine use on the NHS? In June 2025, NICE concluded that the donanemab Alzheimer’s treatment cost-effectiveness does not justify routine ...
How Gene-Editing Therapies Are Revolutionizing ASCVD Treatment and Market Tra...
EMA 2024 Report Highlights: Innovations in Medicine Approval and Regulatory A...
PCV20 Reimbursement Guidelines: Analysis of Dutch Advisory Council Recommenda...
NICE Approves Transformative Multiple Myeloma Treatment
KEYTRUDA Head Neck Cancer Approval: Transforming Treatment and Health Economics
EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Co...
Telemedicine Growth Strategies: Insights from the WHO European Region
Pfizer Conference Insights: Analyzing Bourla’s Strategic Vision Amid Po...
RFK Jr.’s ACIP Overhaul: Examining Vaccine Policy Implications
Elsa – FDA AI Tool: Navigating Efficiency and Ethics
What are the Plans and Implications for Keytruda´s Biosimilar
Revitalizing Innovation: The Impact of UK Medicine Payment Rates